Among patients with high striatum DAT binding (n = 17) prior to therapy, all except one individual responded well to MPH therapy (as estimated by CGI before and after MPH medication), while none of the ADHD patients with low DAT levels (n = 5) showed a significant improvement of ADHD symptoms. The gene discussed is SLC6A3; the disease is attention deficit-hyperactivity disorder.